Top 10 Medical Stocks To Own For 2018

Venezuela faces shortages of food, water, medicine, electricity and money.

But its state-run oil company — through a subsidiary — donated $500,000 to President Trump’s inauguration committee on December 22, 2016.

That equals what Pepsi (PEP), Verizon (VZ, Tech30) and Walmart (WMT) donated combined, according to Federal Election Commission records released Wednesday as deadly protests raged across Venezuela. The donation to Trump’s inauguration committee was made by Citgo Petroleum, a subsidiary of Venezuela’s state-run oil company, PDVSA.

The country’s citizens face a litany of crises — from food and medical shortages to extremely violent crime.

“It is an amazing amount of money that could have fed a lot of your population for the month,” says Russ Dallen, managing partner of Caracas Capital, an investing firm based in Miami.

Venezuela’s state-run oil giant, PDVSA, bought Citgo in the 1980s. When the late President Hugo Chavez took power in 1999, Citgo was a huge money maker for the country.

Top 10 Medical Stocks To Own For 2018: Progressive Corporation (PGR)

Advisors’ Opinion:

  • [By Chris Lange]

    Progressive Corp. (NYSE: PGR) is set to report its third-quarter results Tuesday morning as well. The analysts consensus estimates are $0.36 in EPS on revenue of $6.99 billion. Shares were changing hands at $48.67 on Fridays close. The consensus price target is $49.07, and the 52-week range is $30.99 to $49.75.

  • [By Joseph Griffin]

    Trexquant Investment LP bought a new stake in shares of Progressive Co. (NYSE:PGR) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 60,054 shares of the insurance provider’s stock, valued at approximately $3,659,000.

Top 10 Medical Stocks To Own For 2018: The Descartes Systems Group Inc.(DSGX)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Descartes Systems Group (NASDAQ:DSGX) (TSE:DSG) was upgraded by research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research report issued on Thursday.

Top 10 Medical Stocks To Own For 2018: Gilead Sciences, Inc.(GILD)

Advisors’ Opinion:

  • [By Kumar Abhishek]

    Shares of Foster City, California-based, biotech major, Gilead Sciences, Inc(NASDAQ:GILD) have been on a consistent decline in the last one year or so. After being one of the best performers in the biotech space since 2012, Gilead stock has lost more than 12% in last one year, while theNasdaq Composite (INDX:COMPX) has gained by more than 24% in the same period, resulting in a massive underperformance. Gilead stock has underperformedeven the iShares NASDAQ Biotech Index ETF (NASDAQ:IBB) which has returned more than 14% during the same period. Gilead stock has been making lower lows and lower highs going into the earnings, indicating a clear downtrend in the stock. The stock hit its 52 week low of $69.78 recently on January 24th, just days ahead of its Q4 earnings result. Gilead Sciences, Incis scheduled to report its Q4 2016 and FY 2016 earnings on 7th of February, after the market close.

  • [By Chris Lange]

    Gilead Sciences Inc. (NASDAQ: GILD) has a PDUFA date for its HIV-1 treatment, bictegravir in combination with emtricitabine/tenofovir alafenamide, set on February 12. Shares of Gilead traded at $81.73 apiece, with a consensus price target of $87.79 and a 52-week range of $63.76 to $89.54.

  • [By Keith Speights]

    AbbVie’s new hepatitis C virus (HCV) drug Mavyretappears to be giving Gilead Sciences (NASDAQ:GILD) a run for its money. In the first quarter, AbbVie’s net HCV revenue came in at $919 million. That total includes both of the company’s HCV drugs, Viekira and Mavyret. But there’s virtually no question that Mavyret is contributing most of AbbVie’s HCV revenue.

Top 10 Medical Stocks To Own For 2018: American Capital Agency Corp.(AGNC)

Advisors’ Opinion:

  • [By Amanda Alix]

    This development will likely give battered mREITs like Annaly Capital (NYSE: NLY  ) , Armour Residential (NYSE: ARR  ) , and American Capital Agency (NASDAQ: AGNC  ) a huge boost as investors begin to feel less panic regarding a tapering of the current QE3 program. Markets have responded to the Summers announcement by soaring skyward, apparently feeling relief and confidence about the fate of the taper.

  • [By Boniface Murigu]

    It’s no secret that mREITs such as American Capital Agency (NASDAQ: AGNC  ) (NASDAQ: AGNC  ) (NASDAQ: AGNC  ) , Annaly Capital Management (NYSE: NLY  ) (NYSE: NLY  ) (NYSE: NLY  ) ,and CYS Investmentshave gone through a very turbulent trading period, with all major players losing a sizable share of market value.

  • [By Amanda Alix]

    It was just about one year ago that QE3 made its debut, and mortgage REITs, particularly agency-only players like Annaly Capital (NYSE: NLY  ) , Armour Residential (NYSE: ARR  ) , and American Capital Agency (NASDAQ: AGNC  ) began moaning about the increased competition for mortgage-backed securities guaranteed by Fannie Mae and Freddie Mac.

Top 10 Medical Stocks To Own For 2018: EV Energy Partners, L.P.(EVEP)

Advisors’ Opinion:

  • [By William Romov]

    Before we show you our pick, here are the top 10 penny stocks to watch this week

    Penny Stock Current Share Price Nov. 27-Dec. 1 Gain (as of Dec. 1)
    Pyxis Tankers Inc. (Nasdaq: PXS) $4.10 122.83%
    Ohr Pharmaceuticals Inc. (Nasdaq: OHRP) $1.28 68.42%
    Cerecor Inc. (Nasdaq: CERC) $1.74 47.46%
    Proteostasis Therapeutics Inc. (Nasdaq: PTI) $2.52 37.71%
    UT Starcom Holdings Corp. (Nasdaq: UTSI) $5.20 37.20%
    WMIH Corp. (Nasdaq: WMIH) $0.96 33.46%
    PhaseRx Inc. (Nasdaq: PZRX) $0.90 30.29%
    Bellerophon Therapeutics Inc. (Nasdaq: BLPH) $2.04 29.94%
    EV Energy Partners LP (Nasdaq: EVEP) $0.86 27.76%
    Catalyst Pharmaceuticals Inc. (Nasdaq: CPRX) $4.40 25.71%

    FREE PROFIT ALERTS: Get real-time recommendations on the best penny stock opportunities the moment we release them. Just sign up here, its completely free

  • [By Money Morning Staff Reports]

    But before we show you our pick, here are the top 10 penny stocks to watch this week…

    Penny Stocks Current Share Price (as of Jan. 5) Jan. 2-5 Gain (as of Jan. 5)
    My Size Inc. (Nasdaq: MYSZ) $1.66 152.28%
    Cytori Therapeutics Inc. (Nasdaq: CYTX) $0.47 89.52%
    DelMar Pharmaceuticals Inc. (Nasdaq: DMPI) $1.675 58.02%
    CAS Medical Systems Inc. (Nasdaq: CASM) $1.09 55.71%
    China HGS Real Estate Inc. (Nasdaq: HGSH) $1.83 47.58%
    Aethlon Medical Inc. (Nasdaq: AEMD) $1.56 43.12%
    Midatech Pharma Plc. (Nasdaq: MTP) $1.23 43.01%
    Comstock Holding Cos. Inc. (Nasdaq: CHCI) $1.87 36.5%
    Cenveo Inc. (Nasdaq: CVO) $1.20 31.82%
    EV Energy Partners LP (Nasdaq: EVEP) $0.6844 31.62%

    FREE PROFIT ALERTS: Get real-time recommendations on the best penny stock opportunities the moment we release them. Just sign up here, it’s completely free…

Top 10 Medical Stocks To Own For 2018: Advanced Energy Industries, Inc.(AEIS)

Advisors’ Opinion:

  • [By Nelson Hem]

    While short sellers shied away from many of the leading solar stocks between the January 15 and January 29 settlement dates, two companies in particular led that trend. The number of Advanced Energy Industries, Inc. (NASDAQ: AEIS) and Sunedison Inc (NYSE: SUNE) shares sold short shrank by more than 10 percent by the end of the month.

  • [By Max Byerly]

    Advanced Energy (NASDAQ:AEIS) has received an average rating of “Hold” from the eight research firms that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, three have given a hold recommendation and three have given a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $78.20.

Top 10 Medical Stocks To Own For 2018: Atlantia S.p.A. (ATASF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Atlantia (ATASF) (AT.IM), Eiffage (OTCPK:EFGSY) (FGR.FP), Ferrovial (OTC:FRRVF) (FER.SM), Albertis (OTC:ABFOF) (ABE.SM) and Vinci (OTCPK:VCISF) (DG.FP)

Top 10 Medical Stocks To Own For 2018: Concho Resources Inc.(CXO)

Advisors’ Opinion:

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Monday was Concho Resources Inc. (NYSE: CXO) which traded down about 7% at $140.01. The stocks 52-week range is $106.73 to $162.91. Volume was about 3 million compared to the daily average volume of 1.5 million.

  • [By Paul Ausick]

    Concho Resources Inc. (NYSE: CXO) is also rated a Hold with a higher price target of $150. For 2017, Jefferies raised its EPS estimate from $0.33 to $1.32, and for 2018 the estimate was lifted from $2.91 to $3.50. The stock closed at $132.41 on Friday, in a 52-week range of $94.26 to $147.55, and the consensus 12-month target is $167.46.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Wednesday was Concho Resources Inc. (NYSE: CXO) which traded down about 9% at $143.15. The stocks 52-week range is $106.73 to $162.91. Volume was 11.8 million compared to the daily average volume of 1.3 million.

  • [By Ben Levisohn]

    Lear also sees strong “upside potential” forConcho Resources (CXO), Pioneer Natural Resources (PXD) and Newfield Exploration (NFX) as well performance improves in the Permian/STACK, and also writes positively on Devon Energy (DVN).

  • [By Matthew DiLallo]

    Rising acreage prices are causing Permian peers concern that the market is getting too hot. For example, Concho Resources (NYSE:CXO) recently said that it was having difficulty finding a good value in Permian land deals. That’s saying a lot for a company that completed several deals over the past year, including paying $1.625 billion for 40,000 net acres last August, or more than $40,000 per acre. However, with recent deals in the mid-$40,000s per acre, and up to as high as $58,500 per acre, buyers like Concho are growing cautious, which suggests land values might be topping out.

Top 10 Medical Stocks To Own For 2018: MPLX LP(MPLX)

Advisors’ Opinion:

  • [By Tyler Crowe]

    [T]his morning we announced our 2018 capital investment plans for both MPC and MPLX(NYSE:MPLX). This plan remains focus on strengthening the sustained earnings power of the business through growth and margin enhancing projects as well as expanding our more stable cash flow businesses especially Speedway and MPLX. Our capital plan for MPC for 2018 excluding MPLX is $1.6 billion. This plan spending includes $950 million for Refining & Marketing, $530 million for Speedway and $100 million to support corporate activities and other investments.

  • [By Tyler Crowe]

    So in this spirit, I thought I would share with you a stock you may want to consider for your own portfolio because it is one I have recently purchased myself: oil and gas logistics player MPLX LP (NYSE:MPLX). Here’s why I think it is a company worthy of investment and the recent change to the business that compelled me to buy this stock.

  • [By Garrett Cook]

    Lastly, Citi says Marathon Petroleum (NYSE: MPC) and MPLX LP (NYSE: MPLX) remain Buy rated the heels of benefits derived from strong product demand and the NGL recovery.

  • [By Ben Levisohn]

    JPMorgan analyst Phil Gresh and team explain what they got wrong about Marathon Petroleum (MPC), as they cut its rating to Neutral from Overweight following yesterday’s disastrous financial results from MPLX (MPLX):

Top 10 Medical Stocks To Own For 2018: AbbVie Inc.(ABBV)

Advisors’ Opinion:

  • [By Keith Speights, Brian Stoffel, and George Budwell]

    Healthcare is changing rapidly. Which companies will emerge as the huge winners with these major changes? We asked three of our healthcare contributors to weigh in on the subject. Here’s whyAbbVie (NYSE:ABBV),Alphabet (NASDAQ:GOOGL) (NASDAQ:GOOG), Johnson & Johnson (NYSE:JNJ), and Veeva Systems (NYSE:VEEV) could represent bold bets on the future of healthcare.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Monday was AbbVie Inc. (NYSE: ABBV) which traded down about 2% at $95.21. The stocks 52-week range is $63.12 to $125.86. Volume was nearly 14 million compared to the daily average volume of 6.8 million.

  • [By ]

    Pharmaceutical stocks joined the party Wednesday after Trump dredged up drug pricing concerns during his State of the Union address. Every major drug manufacturer retreated yesterday. Eli Lilly & Co. (NYSE:LLY) led the way lower with a decline of more than 5%. Johnson & Johnson (NYSE:JNJ) and AbbVie (NYSE:ABBV) werent far behind with losses of 3%.